4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001209191-18-035615
Chief Executive Officer sold 13,000 shares at an average $95.35 ($1,239,608)
- Chief Executive Officer acquired 13,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Schenkein David P Chief Executive Officer | 2018-06-01 | Option exercise | +12,892 | $0.47 | $6,027 | 12,892 | D |
| Schenkein David P Chief Executive Officer | 2018-06-01 | Option exercise | +108 | $2.34 | $253 | 13,000 | D |
| Schenkein David P Chief Executive Officer | 2018-06-01 | Sale | −1,510 | $94.37 | $142,499 | 11,490 | D |
| Schenkein David P Chief Executive Officer | 2018-06-01 | Sale | −8,200 | $95.11 | $779,902 | 3,290 | D |
| Schenkein David P Chief Executive Officer | 2018-06-01 | Sale | −3,190 | $96.40 | $307,516 | 100 | D |
| Schenkein David P Chief Executive Officer | 2018-06-01 | Sale | −100 | $96.91 | $9,691 | 0 | D |
| Derivatives | |||||||
| Schenkein David P Chief Executive Officer | 2018-06-01 | Option exercise · Stock option (right to buy) | −12,892 | 0 | D | ||
| Schenkein David P Chief Executive Officer | 2018-06-01 | Option exercise · Stock option (right to buy) | −108 | 72,619 | D | ||
| Open-market sales · 13,000 sh · avg $95.35 · $1,239,608 | |||||||
Loading xslF345X03/doc4.xml…